In a decisive victory, ex-president John Dramani Mahama has been announced as the winner of Ghana's presidential election, securing 56.55% of the vote. His main opponent, Mahamudu Bawumia, conceded defeat on Sunday, acknowledging the public's desire for change. The electoral commission reported that votes were processed from 267 out of 276 constituencies, with a notable 60.9% voter turnout. Mahama, aged 66, who previously led Ghana from 2012 to 2016, criticized Bawumia's platform as a continuation of policies that have resulted in the country's worst economic challenge in decades. Addressing supporters, Mahama emphasized the need to meet public aspirations and avoid governance arrogance. Committing to significant reforms, Mahama plans to renegotiate the $3-billion IMF bailout, reform tax systems, ease business regulations, and invest in infrastructure to revitalize Ghana's economy. (With inputs from agencies.)Suriname rules out state funeral for ex-dictator Bouterse
The long sports-filled Thanksgiving weekend is a time when many Americans enjoy gathering with friends and family for good food, good company and hopefully not too much political conversation. Also on the menu — all the NFL and college sports you can handle. Here's a roadmap to one of the biggest sports weekends of the year, with a look at marquee games over the holiday and how to watch. All times are in EST. All odds are by BetMGM Sportsbook. • NFL: There is a triple-header lined up for pro football fans. Chicago at Detroit, 12:30 p.m., CBS: Rookie quarterback Caleb Williams and the Bears go against the Lions, who are one of the favorites to reach the Super Bowl in February. Lions favored by 10. New York at Dallas, 4:30 p.m., Fox: The Giants and Cowboys are both suffering through miserable seasons and are now using backup quarterbacks for different reasons. But if Dallas can figure out a way to win, it will still be on the fringe of the playoff race. Cowboys favored by 3 1/2. Miami at Green Bay, 8:20 p.m., NBC/Peacock: The Packers stumbled slightly out of the gate but have won six of their past seven games. They'll need a win against Miami to try to keep pace in the NFC North. Packers favored by 3. • College Football: Memphis at No. 18 Tulane, 7:30 p.m., ESPN. If college football is your jam, this is a good warmup for a big weekend. The Tigers try to ruin the Green Wave’s perfect record in the American Athletic Conference. Tulane is favored by 14. Kansas City Chiefs quarterback Patrick Mahomes works in the pocket against the Carolina Panthers during the first half of Sunday's game in Charlotte, N.C. • NFL: A rare Friday showdown features the league-leading Chiefs. Las Vegas at Kansas City, 3 p.m. Prime Video: The Chiefs and quarterback Patrick Mahomes are 12-point favorites over the Raiders. • College Basketball: Some of the top programs meet in holiday tournaments around the country. Battle 4 Atlantis championship, 5:30 p.m., ESPN: One of the premier early season tournaments, the eight-team field includes No. 3 Gonzaga, No. 14 Indiana and No. 24 Arizona. Rady Children's Invitational, 6 p.m., Fox: It's the championship game for a four-team field that includes No. 13 Purdue and No. 23 Mississippi. • College Football: There is a full slate of college games to dig into. Oregon State at No. 11 Boise State, noon, Fox: The Broncos try to stay in the College Football Playoff hunt when they host the Beavers. Boise State favored by 19 1/2. Oklahoma State at No. 23 Colorado, noon, ABC: The Buffaloes and Coach Prime are still in the hunt for the Big 12 championship game when they host the Cowboys. Colorado favored by 16 1/2. Georgia Tech at No. 6 Georgia, 7:30 p.m., ABC: The Bulldogs are on pace for a spot in the CFP but host what could be a tricky game against rival Georgia Tech. Georgia favored by 19 1/2. • NBA. After taking Thanksgiving off, pro basketball returns. Oklahoma City at Los Angeles Lakers, 10 p.m., ESPN: The Thunder look like one of the best teams in the NBA's Western Conference. They'll host Anthony Davis, LeBron James and the Lakers. Los Angeles Lakers forward LeBron James dunks during the first half of a Nov. 23 game against the Denver Nuggets in Los Angeles. • College Football. There are more matchups with playoff implications. Michigan at No. 2 Ohio State, noon, Fox: The Wolverines are struggling one season after winning the national title. They could make their fan base a whole lot happier with an upset of the Buckeyes. Ohio State favored by 21. No. 7 Tennessee at Vanderbilt, noon, ABC: The Volunteers are a fairly big favorite and have dominated this series, but the Commodores have been a tough team this season and already have achieved a monumental upset over Alabama. Tennessee favored by 11. No. 16 South Carolina at No. 12 Clemson, noon, ESPN: The Palmetto State rivals are both hanging on the edge of the CFP playoff race. A win — particularly for Clemson — would go a long way toward clinching its spot in the field. Clemson favored by 2 1/2. No. 3 Texas at No. 20 Texas A&M, 7:30 p.m. ABC: The Aggies host their in-state rival for the first time since 2011 after the Longhorns joined the SEC. Texas favored by 5 1/2. Washington at No. 1 Oregon, 7:30 p.m., NBC: The top-ranked Ducks have been one of the nation’s best teams all season. They’ll face the Huskies, who would love a marquee win in coach Jedd Fisch’s first season. Oregon favored by 19 1/2. • NBA: A star-studded clash is part of the league's lineup. Golden State at Phoenix, 9 p.m., NBA TV: Steph Curry and the Warriors are set to face the Suns' Big Three of Kevin Durant, Devin Booker and Bradley Beal. • NFL: It's Sunday, that says it all. Pittsburgh at Cincinnati, 1 p.m., CBS: Joe Burrow is having a great season for the Bengals, who are struggling in other areas. They need a win to stay in the playoff race, hosting a Steelers team that's 8-3 and won five of their past six. Bengals favored by 3. Arizona at Minnesota, 1 p.m., Fox: The Cardinals are tied for the top of the NFC West while the Vikings are 9-2 and have been one of the biggest surprises of the season with journeyman Sam Darnold under center. Vikings favored by 3 1/2. Philadelphia at Baltimore, 4:25 p.m., CBS: Two of the league's most electric players will be on the field when Saquon Barkley and the Eagles travel to face Lamar Jackson and the Ravens. Ravens favored by 3. San Francisco at Buffalo, 8:20 p.m. NBC/Peacock: The 49ers try to get back to .500 against the Bills, who have won six straight. Bills favored by 7. • NBA. The best teams in the Eastern Conference meet in a statement game. Boston at Cleveland, 6 p.m., NBA TV: The defending champion Celtics travel to face the Cavs, who won their first 15 games to start the season. • Premier League: English soccer fans have a marquee matchup. Manchester City at Liverpool, 11 a.m., USA Network/Telemundo. The two top teams meet with Manchester City trying to shake off recent struggles. • Auto Racing: The F1 season nears its conclusion. F1 Qatar Grand Prix, 11 a.m., ESPN2 – It's the penultimate race of the season. Max Verstappen already has clinched his fourth consecutive season championship. Before the 2023 National Football League season started, it seemed inevitable that Bill Belichick would end his career as the winningest head coach in league history. He had won six Super Bowls with the New England Patriots and 298 regular-season games, plus 31 playoff games, across his career. Then the 2023 season happened. Belichick's Patriots finished 4-13, the franchise's worst record since 1992. At the end of the year, Belichick and New England owner Robert Kraft agreed to part ways. And now, during the 2024 season, Belichick is on the sideline. He's 26 wins from the #1 spot, a mark he'd reach in little more than two seasons if he maintained his .647 career winning percentage. Will he ascend the summit? It's hard to tell. Belichick would be 73 if he graced the sidelines next season—meaning he'd need to coach until at least 75 to break the all-time mark. Only one other NFL coach has ever helmed a team at age 73: Romeo Crennel in 2020 for the Houston Texans. With Belichick's pursuit of history stalled, it's worth glancing at the legends who have reached the pinnacle of coaching success. Who else stands among the 10 winningest coaches in NFL history? Stacker ranked the coaches with the most all-time regular-season wins using data from Pro Football Reference . These coaches have combined for 36 league championships, which represents 31.6% of all championships won throughout the history of pro football. To learn who made the list, keep reading. You may also like: Ranking the biggest NFL Draft busts of the last 30 years - Seasons coached: 23 - Years active: 1981-2003 - Record: 190-165-2 - Winning percentage: .535 - Championships: 0 Dan Reeves reached the Super Bowl four times—thrice with the Denver Broncos and once with the Atlanta Falcons—but never won the NFL's crown jewel. Still, he racked up nearly 200 wins across his 23-year career, including a stint in charge of the New York Giants, with whom he won Coach of the Year in 1993. In all his tenures, he quickly built contenders—the three clubs he coached were a combined 17-31 the year before Reeves joined and 28-20 in his first year. However, his career ended on a sour note as he was fired from a 3-10 Falcons team after Week 14 in 2003. - Seasons coached: 21 - Years active: 1984-98, 2001-06 - Record: 200-126-1 - Winning percentage: .613 - Championships: 0 As head coach of Cleveland, Kansas City, Washington, and San Diego, Marty Schottenheimer proved a successful leader during the regular season. Notably, he was named Coach of the Year after turning around his 4-12 Chargers team to a 12-4 record in 2004. His teams, however, struggled during the playoffs. Schottheimer went 5-13 in the postseason, and he never made it past the conference championship round. As such, the Pennsylvania-born skipper is the winningest NFL coach never to win a league championship. - Seasons coached: 25 - Years active: 1946-62, '68-75 - Record: 213-104-9 - Winning percentage: .672 - Championships: 7 The only coach on this list to pilot a college team, Paul Brown, reached the pro ranks after a three-year stint at Ohio State and two years with the Navy during World War II. He guided the Cleveland Browns—named after Brown, their first coach—to four straight titles in the fledgling All-America Football Conference. After the league folded, the ballclub moved to the NFL in 1950, and Cleveland continued its winning ways, with Brown leading the team to championships in '50, '54, and '55. He was fired in 1963 but returned in 1968 as the co-founder and coach of the Cincinnati Bengals. His other notable accomplishments include helping to invent the face mask and breaking pro football's color barrier . - Seasons coached: 33 - Years active: 1921-53 - Record: 226-132-22 - Winning percentage: .631 - Championships: 6 An early stalwart of the NFL, Curly Lambeau spent 29 years helming the Green Bay Packers before wrapping up his coaching career with two-year stints with the Chicago Cardinals and Washington. His Packers won titles across three decades, including the league's first three-peat from 1929-31. Notably, he experienced only one losing season during his first 27 years with Green Bay, cementing his legacy of consistent success. Born in Green Bay, Lambeau co-founded the Packers and played halfback on the team from 1919-29. He was elected to the Hall of Fame as a coach and owner in 1963, two years before his death. You may also like: Countries with the most active NFL players - Seasons coached: 29 - Years active: 1960-88 - Record: 250-162-6 - Winning percentage: .607 - Championships: 2 The first head coach of the Dallas Cowboys, Tom Landry held the position for his entire 29-year tenure as an NFL coach. The Cowboys were especially dominant in the 1970s when they made five Super Bowls and won the big game twice. Landry was known for coaching strong all-around squads and a unit that earned the nickname the "Doomsday Defense." Between 1966 and 1985, Landry and his Cowboys enjoyed 20 straight seasons with a winning record. He was elected to the Hall of Fame in 1990. - Seasons coached: 29 - Years active: 1991-95, 2000-23 - Record: 302-165 - Winning percentage: .647 - Championships: 6 The most successful head coach of the 21st century, Bill Belichick first coached the Cleveland Browns before taking over the New England Patriots in 2000. With the Pats, Belichick combined with quarterback Tom Brady to win six Super Bowls in 18 years. Belichick and New England split after last season when the Patriots went 4-13—the worst record of Belichick's career. His name has swirled around potential coaching openings , but nothing has come of it. Belichick has remained in the media spotlight with his regular slot on the "Monday Night Football" ManningCast. - Seasons coached: 40 - Years active: 1920-29, '33-42, '46-55, '58-67 - Record: 318-148-31 - Winning percentage: .682 - Championships: 6 George Halas was the founder and longtime owner of the Chicago Bears and coached the team across four separate stints. Nicknamed "Papa Bear," he built the ballclub into one of the NFL's premier franchises behind players such as Bronko Nagurski and Sid Luckman. Halas also played for the team, competing as a player-coach in the 1920s. The first coach to study opponents via game film, he was once a baseball player and even made 12 appearances as a member of the New York Yankees in 1919. He was inducted into the Hall of Fame in 1963 as both a coach and owner. - Seasons coached: 33 - Years active: 1963-95 - Record: 328-156-6 - Winning percentage: .677 - Championships: 2 The winningest head coach in NFL history is Don Shula, who first coached the Baltimore Colts (losing Super Bowl III to Joe Namath and the New York Jets) for seven years before leading the Miami Dolphins for 26 seasons. With the Fins, Shula won back-to-back Super Bowls in 1972 and 1973, a run that included a 17-0 season—the only perfect campaign in NFL history. He also coached quarterback great Dan Marino in the 1980s and '90s, but the pair made it to a Super Bowl just once. Shula was inducted into the Hall of Fame in 1997. Story editing by Mike Taylor. Copy editing by Robert Wickwire. Photo selection by Lacy Kerrick. You may also like: The 5 biggest upsets of the 2023-24 NFL regular season Get local news delivered to your inbox!
Indiaspora has strongly condemned the racist attacks targeting Sriram Krishnan, who was recently appointed by President-elect Donald Trump as Senior AI Advisor. The advisory issued on Saturday emphasized that such attacks have no place in public discourse and stressed the importance of supporting Krishnan’s appointment to this significant role. Indiaspora expressed its unequivocal support for Krishnan, stating, “There is absolutely no room for racially motivated attacks in our discussions. At Indiaspora, we categorically denounce racism in all its forms.” The statement reaffirmed that Krishnan, with his extensive experience in the tech world, will contribute greatly to America’s leadership in artificial intelligence. Indian-American Congressman Ro Khanna also came to Krishnan’s defense, criticizing those who targeted him over his Indian heritage. Khanna highlighted that the ability of the United States to attract top global talent is what sets it apart, emphasizing that American exceptionalism is evident in the diverse backgrounds of leaders like Krishnan. Khanna pointed out that those criticizing Krishnan for being born in India should reconsider their stance, citing the successful careers of figures like Elon Musk (South Africa) and Jensen Huang (Taiwan). Krishnan, who was nominated by Trump as Senior Policy Advisor for Artificial Intelligence at the White House Office of Science and Technology Policy, brings impressive credentials to the role. His career began at Microsoft as a founding member of Windows Azure, and he later served as a General Partner at Andreessen Horowitz. Krishnan has invested in numerous companies, including SpaceX, Figma, and Scale.ai, and has held leadership positions at Meta, X, and Microsoft. In his response to the appointment, Krishnan expressed gratitude, saying, “I’m honored to serve the country and contribute to ensuring continued American leadership in AI, working closely with David Sacks. Thank you, President Trump, for this opportunity.” As part of his new role, Krishnan will focus on strengthening U.S. leadership in AI and collaborating with the President’s Council of Advisors on Science and Technology. He will work closely with David Sacks to shape and coordinate AI policies across government sectors. ALSO READ: The Imminent Threat of World War III: Athos Salomé’s Chilling Predictions
Popular Science Announces the Best Innovations of 2024
" Following the launch and the successful financing of the FOCUS-27 strategic plan, EUROAPI is now on track to deliver long-term value for all its stakeholders. It has been an honor to build and Chair the Board over the past three-plus years, helping this newly formed company navigate headwinds, drive innovation, and improve efficiency. I want to extend my warm thanks to my Board colleagues for their unconditional support and my best wishes to EUROAPI's management and employees for this new chapter of the company, " said Viviane Monges. "On behalf of the Board, I also want to thank Ludwig de Mot for his dedication to EUROAPI since he joined the company. Ludwig has been instrumental in the early implementation of the FOCUS-27 plan, a prerequisite milestone in our path to future profitable growth for the company.” Emmanuel Blin, a Member of the Board since May 2022, is a seasoned executive with extensive experience in the pharmaceutical and healthcare industries. A former Bristol Myers Squibb Executive Committee member, as Chief Strategy Officer and Head of Global Commercialization, he brings EUROAPI a wealth of knowledge and strategic acumen to the role of Chair of the Board. His appointment underscores EUROAPI's commitment to strengthening its position as an Active Pharmaceutical Ingredient industry leader. "I am honored to accept the position of Chair of the Board at EUROAPI. The company is at an exciting juncture, and I look forward to working closely with the Board and the leadership team to continue the transformation initiated by Viviane Monges, whom I'd like to thank for her guidance and devotion to EUROAPI as Chair of the Board for the past three years,” commented Emmanuel Blin. David Seignolle joined EUROAPI's Executive Committee in October 2023, bringing solid experience in the API industry to oversee the Group's Industrial Operations as Chief Operating Officer. He came from TEVA Pharmaceuticals, where he held several international positions, including Head of Operations for TEVA API in Italy and Mexico and Vice President of Global Supply Chain API and Biologics. Before TEVA, David also served five years at McKinsey in France and the US, where he focused on Pharma Operations. "The Board is delighted to promote David as our Chief Executive Officer. Since joining EUROAPI, he has demonstrated strong leadership in a challenging and volatile environment. He has the vision, skills, and rigor needed to drive EUROAPI's transformation and is now well prepared to strengthen the foundations of the company's future development in the best interest of all its stakeholders, including its employees, clients, and shareholders,” commented Elizabeth Bastoni, Chair of the Nominations and Remuneration Committee. On June 26th, the company guided on a -8% to -11% year-on-year net sales decrease on a comparable basis and between 4% and 7% Core EBITDA margin for the full year 2024. Based on the most current figures, EUROAPI maintains this full-year 2024 outlook. Full-year 2024 results will be published on 03 March 2025. About EUROAPI EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers' and patients' needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a large span of technologies while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities. Taking action for health by enabling access to essential therapies inspires our 3,650 people every day. With strong research and development capabilities and six manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Find out more at www.euroapi.com and follow us on LinkedIn . Laurence Bollack Tel.: +33 (0)6 81 86 80 19 [email protected] Sophie Palliez-Capian Tel.: +33 (0)6 87 89 33 51 [email protected] Camille Ricotier Tel : +33 (0)6 43 29 93 79 [email protected] Certain information contained in this press release is forward looking and not historical data. These forward-looking statements are based on opinions, projections and current assumptions including, but not limited to, assumptions concerning the Group's current and future strategy, financial and non-financial future results and the environment in which the Group operates, as well as events, operations, future services or product development and potential. Forward-looking statements are generally identified by the words "expects”, "anticipates”, "believes”, "intends”, "estimates”, "plans” and similar expressions. Forward looking statements and information do not constitute guarantees of future performances, and are subject to known or unknown risks, uncertainties and other factors, a large number of which are difficult to predict and generally outside the control of the Group, which could cause actual results, performances or achievements, or the results of the sector or other events, to differ materially from those described or suggested by these forward-looking statements. These risks and uncertainties include those that are indicated and detailed in Chapter 3 "Risk factors” of the Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers, AMF) on April 5, 2024. These forward-looking statements are given only as of the date of this press release and the Group expressly declines any obligation or commitment to publish updates or corrections of the forward-looking statements included in this press release in order to reflect any change affecting the forecasts or events, conditions or circumstances on which these forward-looking statements are based. Attachment EUROAPI - Press release - December 9, 2024
CARLSBAD, Calif.--(BUSINESS WIRE)--Nov 21, 2024-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the first closing of its previously announced registered direct offering for the purchase and sale of up to an aggregate of 39,473,688 of Lineage’s common shares and accompanying warrants (the “common warrants”) to purchase an aggregate of up to 39,473,688 of Lineage’s common shares at a combined purchase price of $0.76 per common share and accompanying common warrant. Lineage issued an aggregate of 31,578,951 common shares and common warrants to purchase up to 31,578,951 common shares to certain healthcare focused institutional investors in the first closing. Each common warrant will be exercisable for one common share at an exercise price of $0.91 per common share and will be exercisable commencing six months following their date of issuance and will expire on the earlier of (a) the three-year anniversary of the initial exercise date, and (b) the 90th day following the date of the public disclosure of the intent to advance OpRegen ® (also known as RG6501) into a multi-center phase 2 or 3 clinical trial which includes a control or comparator arm, or if the date of such public disclosure occurs prior to the initial exercise date of the common warrants, the 90th day following the initial exercise date. H.C. Wainwright & Co. served as the exclusive placement agent for the offering. The offering of the securities to Broadwood Partners, L.P. (“Broadwood”), an affiliate of Neal Bradsher, a member of Lineage’s board of directors, is expected to close upon obtaining shareholder approval to satisfy applicable NYSE American rules and to the satisfaction of customary closing conditions. The common warrants that may be issued to Broadwood pursuant to the definitive purchase agreement entered into between Lineage and Broadwood will not be exercisable until the later of (i) their date of issuance, which will be the date shareholder approval is obtained, and (ii) the six-month anniversary of the date of issuance of the common warrants to the unaffiliated institutional investors in the offering. Lineage received $24 million in aggregate gross proceeds in the first closing of the offering, which was with respect to the investments by the unaffiliated institutional investors, and expects to receive approximately $6 million in additional gross proceeds from the offering with respect to the investment by Broadwood, in each case, before deducting the placement agent’s fees and other offering expenses payable by Lineage. The potential additional gross proceeds to Lineage from the common warrants, if fully exercised on a cash basis, will be approximately $36 million. No assurance can be given that Lineage will obtain the shareholder approval required to satisfy applicable NYSE American rules in order to sell the securities in the offering to Broadwood or that any of the common warrants will be exercised. Lineage currently plans to use the net proceeds from the offering for working capital and general corporate purposes, including research and development expenses and capital expenditures. The securities described above were offered and sold by Lineage in a registered direct offering pursuant to a “shelf” registration statement on Form S-3 (File No. 333-277758) filed with the Securities and Exchange Commission (the “SEC”) on March 7, 2024, and which was declared effective by the SEC on May 14, 2024. The offering of the securities in the registered direct offering was made only by means of a base prospectus and a prospectus supplement that forms a part of the effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to the offering were filed with the SEC and are available on the SEC’s website at www.sec.gov . Electronic copies of the final prospectus supplement and the accompanying base prospectus may also be obtained from H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com . This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, “off-the-shelf,” cell therapies to address unmet medical needs. Lineage’s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient’s functional activity. Lineage’s neuroscience focused pipeline currently includes: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ReSonanceTM (ANP1), an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Factor Bioscience Limited. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell . Forward-Looking Statements Lineage cautions you that all statements, other than statements of historical fact, in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “aim,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “tend to,” or the negative version of these words and similar expressions. Lineage’s forward-looking statements are based upon its current expectations and beliefs and involve assumptions that may never materialize or may prove to be incorrect. Such statements include, but are not limited to, statements relating to the closing of the offering of the securities to Broadwood, the total potential amount and use of proceeds from the offering, the exercise of the common warrants in cash prior to their expiration and the exercise of the common warrants upon the achievements of such milestone events or otherwise prior to their expiration. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risks that the offering may not close due to the failure to satisfy the applicable closing conditions, including, with respect to the offering of securities to Broadwood, obtaining shareholder approval to satisfy applicable NYSE American rules, and that the common warrants may not be exercised or, if exercised, the exercise price may not be paid in cash, and those risks and uncertainties inherent in Lineage’s business and other risks discussed in Lineage’s filings with the SEC. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the SEC, including Lineage’s most recent Annual Report on Form 10-K filed with the SEC and its other subsequent reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. View source version on businesswire.com : https://www.businesswire.com/news/home/20241121738269/en/ CONTACT: Lineage Cell Therapeutics, Inc. IR Ioana C. Hone (ir@lineagecell.com) (442) 287-8963Russo Partners – Media Relations Nic Johnson or David Schull (Nic.johnson@russopartnersllc.com) (David.schull@russopartnersllc.com) (212) 845-4242 KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: HEALTH NEUROLOGY GENETICS CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Lineage Cell Therapeutics, Inc. Copyright Business Wire 2024. PUB: 11/21/2024 05:00 PM/DISC: 11/21/2024 05:02 PM http://www.businesswire.com/news/home/20241121738269/en
McDonald's mavens are green with envy over a Grinch Happy Meal that's not available in the U.S. McDonald's is offering a holiday-themed Grinch Happy Meal in the U.K. and Ireland through Dec. 31 or while supplies last. Served in a carrying box with the face of the Grinch wearing a Santa hat, the meal comes with trading cards and a plush toy of the Grinch or the dog Max from the classic holiday cartoon "How the Grinch Stole Christmas." And – how could it be so? – there are no plans to bring the Grinch Happy Meal to the U.S. at this time, McDonald's said in a statement to USA TODAY. McDonald's is running TV commercials promoting the meal overseas, and they are also posted on the restaurant's YouTube channels for the U.K. and Ireland . McDonald's: Fast food chain temporarily removes espresso drinks from menus amid reported machine issue Here in the U.S. starting Nov. 26, McDonald's is offering a new Pet Simulator Happy Meal , which comes with two Pet Simulator toys, one for your child and a gift-wrapped toy they can gift to a friend. Could the Grinch Happy Meal come to the US? Never say never. Even though McDonald's said the special Happy Meal is not coming to the U.S. now, that doesn't mean it may not in the future. For instance, last month, the McRib sandwich hit restaurants in the U.K . for a limited time – its first appearance there since 2016. Now, the McRib is returning to the U.S. at participating restaurants nationwide starting Dec. 3 for a limited time. And the Squishmallow Happy Meals offered during the 2023 holiday season here in the U.S. were offered first in the U,K. and Ireland . Based on social media responses, the Grinch Happy Meal would be a hit here in the U.S. as many online are saying "Boo Hoo" about missing out on the meal this holiday season. While you can't get the Happy Meal here, you can participate in some Grinch-related holiday activities found on the McDonald's international sites for the U.K. and Ireland . Follow Mike Snider on X and Threads: @mikesnider & mikegsnider . What's everyone talking about? Sign up for our trending newsletter to get the latest news of the day .
Reports: Bill Belichick interviews for North Carolina jobHe had been diagnosed with terminal liver cancer earlier this year. Mr Gormley’s brother Damian confirmed the news on social media on Monday evening. "It is with profound sadness that I announce my brother Jody passed away peacefully this evening,” he said. His club Trillick St Macartans posted an emotional tribute on their Facebook page, saying the entire community was “devastated”. "The words cannot describe the heartache our club is feeling right now,” said a spokesperson. "Jody was a true red from a young age, playing from underage to senior level. To then managing our senior team to an historical double in 2023. "Jody played for our club from a young age and has been involved in a number of teams throughout his playing career. “He played for Tyrone and won a number of accolades including two u21 All Irelands in 1991 and 1992. “Jody played in the famous 1995 All-Ireland final and scored the only other point bar Peter Canavan’s scores. “Jody was one of a kind and when returned to Trillick brought an aura with him like no other. “Throughout his time with Trillick as player and more recently as a manager he has made an impression on everyone - coaches, players and club members of all levels in a short period of time. "A lot of people will have learnt a lot from him and how to hold themselves. Jody truly is an inspiration, forever our hero and forever a red. "Our most sincere and heartfelt thoughts and prayers are with Jody’s family, his wife Deidre, daughters Áine and Niamh and son James. His mother Shiela, brothers Damian and Eoin and sister Anita.” The Abbey CBS teacher managed the Newry school to its first MacRory Cup title in 19 years back in 2006, finishing the season with a national Hogan Cup title. He managed his club to their ninth Tyrone senior football championship title last year, as well as winning the Tyrone senior league in 2022 and 2023. Jody also took charge at senior intercounty level with Down and Antrim, winning the Tommy Murphy Cup with the latter in 2008. Following his diagnosis, Mr Gormley said he had “no fear whatsoever of dying”. He told the BBC GAA Social Podcast that he “felt blessed his entire life” and spoke of the impact the diagnosis had on his family, reflecting that it was “probably tougher on the family than me”. Podcast host Thomas Niblock paid tribute to Mr Gormley following his death. "Jody Gormley died this evening. Life is so unfair,” he posted on X. "I hope his family can take some comfort, in knowing that he was stunning human being. He was the best of us.” News of his death has led to an outpouring of grief and tributes on social media. First Minister Michelle O’Neill said she was “deeply saddened”. "Throughout his illness, Jody showed incredible strength, courage, and resilience,” she said. “His empowering words will continue to inspire and help so many others as they navigate their own battles in life. "My thoughts are with his family and his many friends throughout the GAA.” Crossmaglen Rangers, who faced Mr Gormley's Trillick side in last year’s Ulster Club championship, also offered their condolences. "Cross Rangers are saddened to learn of the untimely passing of Jody Gormley,” said a spokesperson. “Our thoughts and prayers are with the Gormley family, fellow Gaels in Trillick GAA and Tyrone GAA and colleagues and students at Abbey CBS. "Ar dheis Dé go raibh a anam.” Broadcaster Lynette Fay was also among those paying tribute to Mr Gormley online. "So, so sorry to hear this. Love to Jody Gormley’s family and friends,” she said. "Tá laoch ar lár (A hero is gone).”
FDA chief defends work on obesity, food to Senate